Sequenom Avoids Fine from SEC, Enters Cease-and-Desist Order | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today disclosed that it has entered into a cease-and-desist order with the US Securities and Exchange Commission related to previous public statements regarding its trisomy 21 test, but it will not have to pay any monetary penalties to the commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.